High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: A reappraisal of prognostic factors

Hematological Oncology

Volumn 31, Issue 1, 2013, Pages 34-40

  Cocorocchio, E ^a   Peccatori, F ^a   Vanazzi, A ^a   Piperno, G ^a   Calabrese, L ^a   Botteri, E ^a   Travaini, L ^a   Preda, L ^a   Martinelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Autologous transplant; High dose chemotherapy; Hodgkin lymphoma

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; NAVELBINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH DOSE CHEMOTHERAPY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CISPLATIN; COMBINED MODALITY THERAPY; CYTARABINE; DEOXYCYTIDINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEOPLASM STAGING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 84874937439     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2014     Document Type: Article

References (43)

1. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10(2): 210-218.
2. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15(2): 528-534.
3. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with ABMT in relapsed and resistant Hodgkin's disease, results of a BNLI randomized trial. Lancet 1993; 341: 1051-1054.
4. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071.
5. Bierman PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous rescue in Hodgkin's disease: long term follow-up in 128 patients. Ann Oncol 1993; 4: 767-773.
6. Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, et al. Outcome and prognostic factors in advanced Hodgkin disease treated with high dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004; 15: 1222-1230.
7. Sureda A, Costans M, Iriondo A, et al. Prognostic factors affecting long term out come after stem cell transplantation in Hodgkin's lymphoma autografted after a firs relapse. Ann Oncol 2005; 16: 625-633.
8. Sirohi B, Cunningham D, Powles R, et al. Long term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008; 19: 1312-1319.
9. Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin's lymphoma. N Engl J Med 1998; 339: 1506-1514.
10. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97(3): 616-623.
11. Martín A, Fernández-Jiménez MC, Caballero MD, et al. Long-term follow-up in patients treated with mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001; 113(1): 161-171.
12. Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002; 13(9): 1370-1377.
13. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16: 116-123.
14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
15. Gallamini A, Huthcings M, Rigacci L, et al. Early interim 2-[18] fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
16. 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 2008; 49(4): 727-733.
17. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 211-216.
18. Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin's lymphoma treated with standard salvage chemotherapy and autologous stem cell transplant. Biol Blood Marrow Transplant 2001; 17: 1646-1652.
19. Moskowitz AJ, Yahalom J, Kewalramani T. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116(23): 4934-4937.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
21. Martinelli G, Cocorocchio E, Peccatori F, et al. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. Br J Haematol 2004; 125(5): 584-589.
22. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New Engl J Med 1992; 327(21): 1478-1484.
23. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22(14): 2835-2841.
24. Martinelli G, Cocorocchio E, Saletti PC, et al. Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients. Leuk Lymphoma 2003; 44(11): 1919-1923.
25. Lauria F, Baccarani M, Barbieri E, et al. Combination chemotherapy (MOPP) in 60 patients with Hodgkin's disease (five years results). Haematologica 1975; 60(1): 73-84.
26. Watts MJ, Sullivan AM, Jamieson E, et al. Progenitor cell mobilisation after low-dose cyclophosphamide and G-CSF: an analysis of progenitor cell quality and factors predicting for these parameters in 101 pre-treated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535-546.
27. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 2006; 37: 277-282.
28. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17(12): 3776-3785.
29. Magagnoli M, Spina M, Balzarotti M, et al. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant 2007; 40(11): 1019-1025.
30. Corsini C, Ghielmini M, Mancuso P, et al. Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin. Br J Cancer 2000; 82(3): 524-528.
31. Fermé C, Mounier N, Diviné M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20(2): 467-475.
32. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3(2): 143-152.
33. Lazarus HM, Loberiza FR Jr, Zhang MJ, et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant. Bone Marrow Transplant 2001; 27(4): 387-396.
34. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27(14): 2328-2338.
35. Ng AK, Bernardo MVP, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100(6): 1989-1996.
36. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109(5): 1878-1886.
37. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010; 55(6): 1145-1152.
38. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101(2): 420-424.
39. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146(2): 171-179.
40. Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41(9): 765-770.
41. Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 2009; 147(1): 97-101.
42. Böll B, Borchmann P, Topp MS, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010; 148(3): 480-482.
43. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85(5): 320-324.